Patent intelligence · US
US 9433666
Indoleamine 2,3-dioxygenase based immunotherapy
Indoleamine 2,3-dioxygenase based immunotherapy
Patent details — US 9433666
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 6, 2016
- Expiration
- Sep 1, 2036
- Applicant
- IO Biotech ApS
- Claims
- 2
- CPC classes
- A61K, A61K2039/5158, A61K2039/55566, A61K2039/572
Quick answer
US 9433666 (Indoleamine 2,3-dioxygenase based immunotherapy) is held by IO Biotech ApS. Status: granted. Granted Sep 6, 2016. Expires Sep 1, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- IO Biotech ApS
- Grant date
- Expiration
- Claims
- 2
- CPC classes
- A61K, A61K2039/5158, A61K2039/55566, A61K2039/572, A61K38/193, A61K38/2013
More from IO Biotech ApS
Related pharmaceutical patents in our USPTO index.
-
US 12234288
Immunogenic arginase 2 polypeptides
granted -
US 12233103
Indoleamine 2,3-dioxygenase based immunotherapy
granted -
US 12215135
PDL2 compounds
granted -
US 12194081
ARGINASE1 polypeptides
granted -
US 12187782
PDL1 peptides for use in cancer vaccines
granted -
US 12077785
Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating Krebs cycle and therapeutic uses thereof
granted -
US 11981944
Immunogenic arginase peptides
granted -
US 11878053
Vaccine compositions comprising tryptophan 2,3-dioxygenase or fragments thereof
granted
Related coverage
Frequently asked questions
What is US patent 9433666?
US 9433666 (Indoleamine 2,3-dioxygenase based immunotherapy) is held by IO Biotech ApS. Status: granted. Granted Sep 6, 2016. Expires Sep 1, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9433666?
IO Biotech ApS is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.
When does US 9433666 expire?
Our index shows an expiration date of Sep 1, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.